This study was performed to clarify the influence of Helicobacter pylori on the platelet count in patients undergoing bone marrow transplantation (BMT) from unrelated donors. Of 23 consecutive patients undergoing BMT from unrelated donors, the H. pylori antibody test did not change from before conditioning until recovery of the platelet count in 15 patients. These patients were classified into H. pylori antibody-positive (n ¼ 8) and -negative (n ¼ 7) groups. In the H. pylori antibody-positive group, the platelet count exceeded 20 Â 10 9 /l significantly faster after BMT, than in the H. pylori antibody-negative group. When myelosuppression was most severe, the interleukin-6 (IL-6) level was significantly higher in the positive group than in the negative group (67.0710.6 vs 9.972.4 pg/ml, Po0.05). In addition, the thrombopoietin level was significantly lower in the positive group than in the negative (510.17313.9 vs 3209.172006.7 pg/ml, Po0.01). These data suggest that H. pylori infection accelerates recovery of the platelet count after BMT from unrelated donors, possibly by stimulating IL-6 production.
Introduction
Stem cell transplantation has become an increasingly common therapy not only for hematopoietic malignancies, but also for autoimmune diseases and solid tumors. [1] [2] [3] With respect to the recovery of hematopoietic function after bone marrow transplantation (BMT), the availability of granulocyte-colony stimulating factor (G-CSF) therapy has made it possible to accelerate markedly recovery of the white blood cell count, but recovery of the platelet count generally remains slow, although it varies widely among patients. Consequently, complications resulting from slow recovery of the platelet count are one of the factors responsible for a poor prognosis after BMT. Marshall and Warren 4 first detected Helicobacter pylori in 1984. Since then, its influence on the treatment and recurrence of peptic ulcer, as well as on gastric cancer, the heart, and other organs has been reported. [5] [6] [7] [8] In addition, Emilia et al. 9 have reported that H. pylori might be involved in idiopathic thrombocytopenic purpura (ITP). In the present study, we attempted to clarify the influence of H. pylori on recovery of the platelet count after stem cell transplantation from unrelated donors.
Materials and methods
Informed consent was obtained from each patient and the study was performed in accordance with the ethical standards laid down in the 1975 Declaration of Helsinki. This was a retrospective study.
Patients
A total of 23 patients underwent BMT from fully human leukocyte antigen (HLA)-matched (at the DNA level) unrelated donors at this hospital between May 1996 and May 2000. Before myeloablative therapy for conditioning, the H. pylori antibody titer was positive and negative in 10 and 13 patients, respectively. In eight of the 23 patients, the antibody titer changed from positive to negative or from negative to positive during the period from before conditioning until recovery of the platelet count. The titer remained unchanged (stayed positive or negative) during this period in the other 15 patients, and the present study was performed on these 15 patients, who were classified into H. pylori antibody-positive(n ¼ 8) and Ànegative(n ¼ 7). Table 1 summarizes the age, sex, underlying disease, conditioning regimen, and graft-versus-host disease (GVHD) prophylaxis in each group of patients. Based on the results of an analysis of BMT patients from unrelated donors reported by Davies et al, 10 factors that affect the recovery of leukocytes and platelets, namely, (1) serological matching of the HLA-A, B and DRB1, (2) number of injected cells, (3) age of the recipient, (4) sex of the donor, and (5) CMV seronegativity of recipients were all compared (Table 2) .
Test methods to identify the activity of H. pylori infections such as the urease breath test 11 are very accurate, but there were limitations because this is a retrospective study and the study was conducted using serum antibody tests. The antibody titer becomes positive and remains so for long periods in some cases. Therefore, because past infections rather than current infections might be observed in such cases, and there was a risk of false-positive results, efforts were made to draw conclusions based on a careful investigation of the results obtained.
Conditioning regimen
The conditioning agents were busulfan (American Home Products Corporation Madison, USA), cyclophosphamide (Bristol-Myers Squibb, NY, USA), and total body irradiation (busulfan at a dose of 4 mg/kg/day Â 2 days, cyclophosphamide at 30 mg/kg/day Â 2 days, and irradiation at 3 Gy Â 4).
GVHD prophylaxis
The basic treatment was cyclosporin (CsA) (Novartis, Basel, Switzerland) plus methotrexate (American Home Products Corporation Madison, USA) with or without methylprednisolone (Pharmacia Corporation, Peapack, USA). 12 CsA was infused for 24 h from day À1, and was kept at a target blood level of 400-600 ng/ml until marrow engraftment, after which the dosage was varied depending on the symptoms. If GVHD became worse, the doses of CsA and methylprednisolone were increased or CsA was replaced with tacrolimus hydrate (Fujisawa Pharmacetical Co. Ltd, Osaka, Japan).
Assay of H. pylori
An ELISA kit (Pilicaplate G Helicobacter-II; Fujirebio Inc., Tokyo, Japan) was employed to detect serum H. pylori antibodies. Although it is clear that this method is not as satisfactory as the urease test method in the identification of current H. pylori infection activity, this method has proved useful for detecting infection with H. pylori, and also for determining whether H. pylori eradication therapy has been successful.
Cytokines such as interleukin (IL)-3, IL-6, IL-8, IL-11, and thromboprotein (TPO) 9, 10, [13] [14] [15] have an influence on the platelet count after BMT. These cytokines were measured several times until recovery of the platelet count, and the values in the H. pylori-positive group were compared with those in the H. pylori-negative group.
Blood sampling and assays
Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 rpm for 10 min at 41C, plasma was stored at À801C.
Levels of the following cytokines and factors were investigated: IL-3, IL-6, IL-8, and IL-11, and TPO. Each parameter was measured in duplicate at each time of assessment using ELISA kits (Endogen, Woburn, MA, USA) and the mean value was calculated. The number of days required to reach an ANC40.5 Â 10 Acute GVHD, thrombotic microangiopathy (TMA), and infection with cytomegalovirus (CMV) and human herpesvirus (HHV)-6 have been suggested as factors with an influence on the platelet count. These factors were also compared between the two groups over time until recovery of the platelet count.
Statistical analysis
Statistical analysis was conducted using the Mann-Whitney U-test and Po0.05 was considered to indicate a significant difference.
Results
No significant differences were observed in age, sex, disease stage, and GVHD prophylaxis between the two groups, and the conditioning regimen was the same in all patients ( Table 1 ). The two groups also showed no significant differences in serological matching rates of HLA-A, B and DRB1, number of cell injections, age of recipients sex of donors, and seronegativity of recipients ( Table 2) .
None of the patients developed acute GVHD, TMA, or infection with CMV or HHV-6 before recovery of the platelet count in either group. After engraftment, acute GVHD tended to be less severe in the H. pylori-positive group than in the H. pylori-negative group. There were no significant differences between the two groups with respect to other factors. This result agreed with the fact that delayed platelet recovery is a strong predictive factor for acute GVHD of grade 2 or higher in the cases reported by Davies et al. 10 The underlying disease was lymphoblastic lymphoma in one patient and chronic myelogenous leukemia in two patients in the antibody-positive group but not in the negative group. In the negative group, six patients had acute leukemia, but only four had acute leukemia in the positive group. The capacity of each underlying disease to respond to BMT differs and as a result, two groups that were not completely matched were compared but in an analysis of many BMT cases from unrelated donors, factors that significantly affect the recovery of leukocytes and platelets showed no significant differences between the groups, indicating that these differences in background are within the permissible range.
The number of days required to achieve an ANC40.5 Â 10 /l was achieved earlier in the H. pylori-positive group than in the H. pylori-negative group (Table 3) .
Among the cytokines studied, there were significant differences in IL-6 and TPO levels between the H. pyloripositive and -negative groups. During the period of myelosuppression, the IL-6 level in the H. pylori-positive group (67.0710.6 pg/ml) was significantly higher than the level in the H. pylori-negative group (9.972.4 pg/ml) (Po0.05). During this period, the TPO level in the H. pylori-positive group (510.17313.9) was significantly lower than that in the H. pylori-negative group (3209.172006.7) (Po0.01). Other cytokines (IL-3, IL-6, IL-8, and IL-11) showed no significant differences between the two groups (data not shown).
Discussion
Before conditioning, H. pylori antibodies were positive in 10 (43.5%) of the 23 patients. This positive rate was comparable to that in many previous reports. [16] [17] [18] [19] [20] Despite the administration of antibiotics at high doses, H. pylori antibodies remained positive throughout the course after BMT in many (70%) of these patients. The results obtained in the present study appear to support the fact that many patients in whom H. pylori infection has resolved have residual antibody titers in the serum as described in Materials and methods. In the two groups compared in this study, all patients included received fully HLAmatched bone marrow cells from unrelated donors and the conditioning regimen and GVHD prophylaxis were thus always the same. In addition, background factors such as acute GVHD and CMV infection that might have affected recovery of the platelet count were also similar. Although the number of patients studied was small, recovery of the granulocyte count required almost the same number of days in both groups, whereas recovery of the platelet count showed a significant difference between the two groups. Among the cytokines studied, the IL-6 and TPO levels were different between the two groups, being significantly higher and lower, respectively, in the H. pyloripositive group and the H. pylori-negative group. When these findings are combined, it can be suggested that H. pylori stimulates production of IL-6 during the period of myelosuppression, causing elevation of the serum IL-6 level that accelerates recovery of the platelet count.
After platelet recovery, the production of TPO is suppressed. However, no reports have appeared on the role of H. pylori infection in the production of IL-6 and TPO. There are also no reports on H. pylori antibodies. This appears to be because this result shows the response of IL-6 to systemic infection and not specifically to H. pylori infection. Ljungman et al 21 also recently reported that HHV-6 infection is related to platelet recovery, but it may also be the result of a reaction to IL-6 as an inflammatory cytokine caused by HHV-6 infection. It seems that the synthesis of IL-6 was increased because of stimulation by H. pylori, so it is possible that the production of TPO was suppressed secondary to the increase in platelets induced by IL-6. However, another possible mechanism is that H. pylori directly suppressed the production of TPO.
According to Davies et al, 10 the factors that accelerate recovery of platelets in unrelated donor BMT patient are (1) high cell dose, (2) DRB1 matched marrow, (3) HLA-A and B serologically matched marrow, (4) recipient seronegativity for CMV, (5) female recipient, (6) male donor, and (7) younger recipient. In acute GVHD of grade 2 or higher, there is a strong relation with platelet recovery rate (Po0.0001). Chronic GVHD also shows a relation but it is weak (P ¼ 0.04). Platelet recovery is also related to survival rate because bleeding is often a cause of death after BMT. Such platelet recovery does not appear to be as important as recovery of neutrophils, which is directly related to survival after serious infections, but it is possible that the presence of H. pylori antibodies might become a more important predictive factor for survival than neutrophils in the future, based on the H. pylori-negative and -positive results in the present study. Further studies on this point are warranted.
